Adage Capital Partners Gp, L.L.C. Fate Therapeutics Inc Transaction History

Adage Capital Partners Gp, L.L.C.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$3.26 - $7.08 $4.14 Million - $8.99 Million	-1,270,000 Reduced 59.35%	870,000 $2.85 Million
Q1 2024 May 15, 2024	BUY	$3.54 - $8.35 $1.56 Million - $3.67 Million	440,000 Added 25.88%	2,140,000 $15.7 Million
Q4 2023 Feb 14, 2024	BUY	$1.65 - $3.94 $2.81 Million - $6.7 Million	1,700,000 New	1,700,000 $6.36 Million
Q4 2020 Feb 16, 2021	SELL	$38.09 - $100.95 $1.68 Million - $4.44 Million	-44,000 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$30.41 - $40.5 $1.34 Million - $1.78 Million	44,000 New	44,000 $1.76 Million

167

101M

41.3K

15.9K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $166M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.